Cooperation of Adenosine with Macrophage Toll-4 Receptor Agonists Leads to Increased Glycolytic Flux Through the Enhanced Expression of PFKFB3 Gene
Overview
Authors
Affiliations
Macrophages activated through Toll receptor triggering increase the expression of the A(2A) and A(2B) adenosine receptors. In this study, we show that adenosine receptor activation enhances LPS-induced pfkfb3 expression, resulting in an increase of the key glycolytic allosteric regulator fructose 2,6-bisphosphate and the glycolytic flux. Using shRNA and differential expression of A(2A) and A(2B) receptors, we demonstrate that the A(2A) receptor mediates, in part, the induction of pfkfb3 by LPS, whereas the A(2B) receptor, with lower adenosine affinity, cooperates when high adenosine levels are present. pfkfb3 promoter sequence deletion analysis, site-directed mutagenesis, and inhibition by shRNAs demonstrated that HIF1α is a key transcription factor driving pfkfb3 expression following macrophage activation by LPS, whereas synergic induction of pfkfb3 expression observed with the A(2) receptor agonists seems to depend on Sp1 activity. Furthermore, levels of phospho-AMP kinase also increase, arguing for increased PFKFB3 activity by phosphorylation in long term LPS-activated macrophages. Taken together, our results show that, in macrophages, endogenously generated adenosine cooperates with bacterial components to increase PFKFB3 isozyme activity, resulting in greater fructose 2,6-bisphosphate accumulation. This process enhances the glycolytic flux and favors ATP generation helping to develop and maintain the long term defensive and reparative functions of the macrophages.
Pathogenic role of PFKFB3 in endothelial inflammatory diseases.
Zhou L, Li J, Wang J, Niu X, Li J, Zhang K Front Mol Biosci. 2024; 11:1454456.
PMID: 39318551 PMC: 11419998. DOI: 10.3389/fmolb.2024.1454456.
Wang M, Flaswinkel H, Joshi A, Napoli M, Masgrau-Alsina S, Kamper J Nat Commun. 2024; 15(1):6438.
PMID: 39085210 PMC: 11291651. DOI: 10.1038/s41467-024-50104-7.
Genomic Deletion of PFKFB3 Decreases In Vivo Tumorigenesis.
Imbert-Fernandez Y, Chang S, Lanceta L, Sanders N, Chesney J, Clem B Cancers (Basel). 2024; 16(13).
PMID: 39001392 PMC: 11240529. DOI: 10.3390/cancers16132330.
Dysregulated cellular metabolism in atherosclerosis: mediators and therapeutic opportunities.
Stroope C, Nettersheim F, Coon B, Finney A, Schwartz M, Ley K Nat Metab. 2024; 6(4):617-638.
PMID: 38532071 PMC: 11055680. DOI: 10.1038/s42255-024-01015-w.
Inflammaging and fatty acid oxidation in monocytes and macrophages.
Kruglov V, Jang I, Camell C Immunometabolism (Cobham). 2024; 6(1):e00038.
PMID: 38249577 PMC: 10798594. DOI: 10.1097/IN9.0000000000000038.